{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:35:37Z","timestamp":1791430537510,"version":"4.3.3"},"reference-count":106,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Background: Multiple myeloma (MM) is a complex hematological malignancy characterized by the clonal expansion of plasma cells in the bone marrow. Emerging studies have emphasized the importance of lipid metabolism, which is closely associated with the survival, proliferation, and drug resistance of tumor cells. The hypoxic environment in the bone marrow (BM) contributes to metabolic reprogramming in MM cells, including alterations in metabolite levels, changes in metabolic enzyme activity, and metabolic shifts. Cancer cells possess the ability to adapt their metabolism in order to fulfill their continuously increasing energy demands. In this review, we will discuss the alterations in lipid metabolism during the development of MM, and their reciprocal interactions with the tumor microenvironment.<\/jats:p>","DOI":"10.3389\/fonc.2025.1531928","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T07:10:31Z","timestamp":1741158631000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Lipid metabolism in multiple myeloma: pathogenesis, therapeutic opportunities, and future directions"],"prefix":"10.3389","volume":"15","author":[{"given":"Huiquan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiafeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hefei","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jigang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongkun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-023-01174-2","article-title":"Lipid metabolic vulnerabilities of multiple myeloma","volume":"23","author":"Torcasio","year":"2023","journal-title":"Clin Exp Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111430","article-title":"Metabolic disorders in multiple myeloma","volume":"22","author":"Gavriatopoulou","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013832","article-title":"Multiple myeloma cells induce lipolysis in adipocytes and uptake fatty acids through fatty acid transporter proteins","volume":"139","author":"Panaroni","year":"2022","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40164-022-00303-z","article-title":"Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma","volume":"11","author":"Oudaert","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.925807","article-title":"Role of sphingolipids in multiple myeloma progression, drug resistance, and their potential as therapeutic targets","volume":"12","author":"Petrusca","year":"2022","journal-title":"Front Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"101856","DOI":"10.1016\/j.tranon.2023.101856","article-title":"Bone marrow adipocytes is a new player in supporting myeloma cells proliferation and survival in myeloma microenvironment","volume":"40","author":"Wei","year":"2024","journal-title":"Transl Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2014.12.010","article-title":"Plasma fatty acid profile in multiple myeloma patients","volume":"39","author":"Jurczyszyn","year":"2015","journal-title":"Leuk Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10173","article-title":"Multiple myeloma and fatty acid metabolism","volume":"3","author":"Masarwi","year":"2019","journal-title":"JBMR Plus"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1182\/blood-2021-146902","article-title":"Fatty acid binding proteins as a novel therapeutic target in multiple myeloma","volume":"138","author":"Farrell","year":"2021","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.81184.sa2","article-title":"Targeting the fatty acid binding proteins disrupts multiple myeloma cell cycle progression and MYC signaling","volume":"12","author":"Farrell","year":"2023","journal-title":"Elife"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.897862","article-title":"Multiple myeloma metabolism - a treasure trove of therapeutic targets","volume":"13","author":"Roman-Trufero","year":"2022","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40170-020-00235-4","article-title":"In vivo assessment of glutamine anaplerosis into the TCA cycle in human pre-malignant and Malignant clonal plasma cells","volume":"8","author":"Gonsalves","year":"2020","journal-title":"Cancer Metab"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30070455","article-title":"Tumor-associated macrophages in multiple myeloma: key role in disease biology and potential therapeutic implications","volume":"30","author":"Cencini","year":"2023","journal-title":"Curr Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07114.x","article-title":"Fatty acid synthase is a novel therapeutic target in multiple myeloma","volume":"141","author":"Okawa","year":"2008","journal-title":"Br J Haematol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"19522","DOI":"10.1111\/j.1365-2141.2008.07114.x","article-title":"Inhibition of fatty acid synthase induces anti-tumor effect in multiple myeloma","volume":"26","author":"Okawa","year":"2008","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"4849","DOI":"10.1182\/blood.V104.11.4849.4849","article-title":"Fatty acid synthase inhibitor induces apoptosis and inhibits proliferation in multiple myeloma cells","volume":"104","author":"Wang","year":"2004","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.3390\/cells10092287","article-title":"Omega-3 fatty acids DHA and EPA reduce bortezomib resistance in multiple myeloma cells by promoting glutathione degradation","volume":"10","author":"Chen","year":"2021","journal-title":"Cells"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.584683","article-title":"Multiple myeloma cells alter adipogenesis, increase senescence-related and inflammatory gene transcript expression, and alter metabolism in preadipocytes","volume":"10","author":"Fairfield","year":"2020","journal-title":"Front Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3390\/biomedicines12030514","article-title":"Protective effects of high-density lipoprotein on cancer risk: focus on multiple myeloma","volume":"12","author":"Allegra","year":"2024","journal-title":"Biomedicines"},{"key":"B20","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1182\/blood.2022016892","article-title":"A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth","volume":"141","author":"Morelli","year":"2023","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/ncrna9010016","article-title":"Non-coding RNA-dependent regulation of mitochondrial dynamics in cancer pathophysiology","volume":"9","author":"Gallo Cantafio","year":"2023","journal-title":"Noncoding RNA"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10061295","article-title":"Epigenetic regulation of mitochondrial quality control genes in multiple myeloma: A sequenom massARRAY pilot investigation on HMCLs","volume":"10","author":"D'aquila","year":"2021","journal-title":"J Clin Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12967-024-05013-","article-title":"Targeting of mitochondrial fission through natural flavanones elicits anti-myeloma activity","volume":"22","author":"Torcasio","year":"2024","journal-title":"J Transl Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00397.2004","article-title":"Adiponectin inhibits LPS-induced NF-kappaB activation and IL-6 production and increases PPARgamma2 expression in adipocytes","volume":"288","author":"Ajuwon","year":"2005","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/BF02983377","article-title":"Survival and proliferation factors of normal and Malignant plasma cells","volume":"78","author":"Klein","year":"2003","journal-title":"Int J Hematol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2004.08.145","article-title":"Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes [J","volume":"323","author":"Wolf","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.09.010","article-title":"Mechanism of fatty-acid-dependent UCP1 uncoupling in brown fat mitochondria","volume":"151","author":"Fedorenko","year":"2012","journal-title":"Cell"},{"key":"B28","doi-asserted-by":"publisher","first-page":"109336","DOI":"10.1016\/j.cellsig.2019.06.001","article-title":"Role of fatty acid binding proteins (FABPs) in cancer development and progression","volume":"62","author":"Mckillop","year":"2019","journal-title":"Cell Signal"},{"key":"B29","doi-asserted-by":"publisher","first-page":"102284","DOI":"10.1016\/j.ctrv.2021.102284","article-title":"Roadmap to cure multiple myeloma","volume":"100","author":"Rodriguez-Otero","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-078022","article-title":"Multiple myeloma","volume":"111","author":"Kyle","year":"2008","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2020.08.027","article-title":"Glucocorticoid induced diabetes and lipid profiles disorders amongst lymphoid Malignancy survivors","volume":"14","author":"Dehghani","year":"2020","journal-title":"Diabetes Metab Syndr"},{"key":"B32","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1159\/000355826","article-title":"Multiple myeloma: relationship to antioxidant esterases","volume":"23","author":"Ellidag","year":"2014","journal-title":"Med Princ Pract"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.7314\/APJCP.2014.15.22.9847","article-title":"Decreased HDL-dependent paraoxonase and arylesterase enzyme activity may indicate a worse prognosis in multiple myeloma","volume":"15","author":"Ellidag","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1179\/1351000215Y.0000000034","article-title":"Serum 8-isoprostane levels and paraoxonase 1 activity in patients with stage I multiple myeloma","volume":"21","author":"Faridvand","year":"2016","journal-title":"Redox Rep"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1515\/cclm.1987.25.10.675","article-title":"Quantitative abnormalities of lipoprotein particles in multiple myeloma","volume":"25","author":"Hachem","year":"1987","journal-title":"J Clin Chem Clin Biochem"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/0005-2760(88)90291-3","article-title":"Evidence for qualitative abnormalities in high-density lipoproteins from myeloma patients: the presence of amyloid A protein could explain HDL modifications","volume":"963","author":"Hachem","year":"1988","journal-title":"Biochim Biophys Acta"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(99)00083-1","article-title":"Metabolism of an artificial emulsion resembling chylomicrons in patients with multiple myeloma","volume":"23","author":"Hungria","year":"1999","journal-title":"Leuk Res"},{"key":"B38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s10552-017-0991-y","article-title":"Serum lipids and risk of obesity-related cancers in postmenopausal women","volume":"29","author":"Kabat","year":"2018","journal-title":"Cancer Causes Control"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-017-0991-y","article-title":"Chemotherapy-associated changes in 31P MRS spectra of sera from patients with multiple myeloma","volume":"8","author":"Kuliszkiewicz-Janus","year":"1995","journal-title":"NMR BioMed"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.2478\/s11658-008-0014-9","article-title":"Lipid changes occuring in the course of hematological cancers","volume":"13","author":"Kuliszkiewicz-Janus","year":"2008","journal-title":"Cell Mol Biol Lett"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.60.705.449","article-title":"Plasma cholesterol concentration and extra lipid band in monoclonal gammopathies","volume":"60","author":"Levy","year":"1984","journal-title":"Postgrad Med J"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-020-00926-7","article-title":"A non-invasive differential diagnostic model for light chain cast nephropathy in newly diagnosed multiple myeloma patients with renal involvement: a multicenter study","volume":"34","author":"Lin","year":"2021","journal-title":"J Nephrol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-007-0375-6","article-title":"Cholesterol levels in patients with multiple myeloma","volume":"87","author":"Yavasoglu","year":"2008","journal-title":"Ann Hematol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.7150\/jca.31357","article-title":"Identification of high serum apolipoprotein A1 as a favorable prognostic indicator in patients with multiple myeloma","volume":"10","author":"Liang","year":"2019","journal-title":"J Cancer"},{"key":"B45","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1186\/s12944-024-02289-5","article-title":"Lipid levels and multiple myeloma risk: insights from Meta-analysis and mendelian randomization","volume":"23","author":"Zhu","year":"2024","journal-title":"Lipids Health Dis"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2016.07.012","article-title":"Adipocyte-lineage cells support growth and dissemination of multiple myeloma in bone","volume":"186","author":"Trotter","year":"2016","journal-title":"Am J Pathol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejim.2018.05.033","article-title":"The adipose organ and multiple myeloma: Impact of adipokines on tumor growth and potential sites for therapeutic intervention","volume":"53","author":"Allegra","year":"2018","journal-title":"Eur J Intern Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.v6i33","article-title":"Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation","volume":"6","author":"Liu","year":"2015","journal-title":"Oncotarget"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau9087","article-title":"Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease","volume":"11","author":"Liu","year":"2019","journal-title":"Sci Transl Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00788","article-title":"Interleukin-6 interweaves the bone marrow microenvironment, bone loss, and multiple myeloma","volume":"9","author":"Harmer","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00339","article-title":"Bone marrow adipocyte: an intimate partner with tumor cells in bone metastasis","volume":"9","author":"Luo","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B52","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40164-020-00196-w","article-title":"Targeting phosphoglycerate dehydrogenase in multiple myeloma","volume":"10","author":"Elsaadi","year":"2021","journal-title":"Exp Hematol Oncol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.chembiol.2020.03.014","article-title":"Achieving life through death: redox biology of lipid peroxidation in ferroptosis","volume":"27","author":"Bayir","year":"2020","journal-title":"Cell Chem Biol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41408-019-0191-y","article-title":"Natural history of multiple myeloma with de novo del(17p)","volume":"9","author":"Lakshman","year":"2019","journal-title":"Blood Cancer J"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24351","article-title":"Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPin((R)) protein MP0250: a preclinical study","volume":"9","author":"Rao","year":"2018","journal-title":"Oncotarget"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1080\/1042819031000083262","article-title":"Predicting treatment responses and disease progression in myeloma using serum vascular endothelial growth factor and hepatocyte growth factor levels","volume":"44","author":"Iwasaki","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1038\/s41467-023-37501-0","article-title":"DAXX drives de novo lipogenesis and contributes to tumorigenesis","volume":"14","author":"Mahmud","year":"2023","journal-title":"Nat Commun"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003975","article-title":"Tumor-associated macrophages in multiple myeloma: advances in biology and therapy","volume":"10","author":"Sun","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"key":"B59","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jare.2024.02.009","article-title":"Targeting lipid metabolism of macrophages: A new strategy for tumor therapy","volume":"68","author":"Shao","year":"2025","journal-title":"J Adv Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12944-023-01807-1","article-title":"Lipid metabolism reprogramming in tumor-associated macrophages and implications for therapy","volume":"22","author":"Qiao","year":"2023","journal-title":"Lipids Health Dis"},{"key":"B61","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1471-2172-13-31","article-title":"TGFbeta signaling plays a critical role in promoting alternative macrophage activation","volume":"13","author":"Gong","year":"2012","journal-title":"BMC Immunol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s41388-020-01536-0","article-title":"CSF1R inhibition depletes tumor-associated macrophages and attenuates tumor progression in a mouse sonic Hedgehog-Medulloblastoma model","volume":"40","author":"Tan","year":"2021","journal-title":"Oncogene"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1000413","article-title":"Tumor-conditioned macrophages secrete migration-stimulating factor: a new marker for M2-polarization, influencing tumor cell motility","volume":"185","author":"Solinas","year":"2010","journal-title":"J Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/nature13490","article-title":"Functional polarization of tumour-associated macrophages by tumour-derived lactic acid","volume":"513","author":"Colegio","year":"2014","journal-title":"Nature"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/s41563-020-00849-5","article-title":"Tumour-associated macrophages drive stromal cell-dependent collagen crosslinking and stiffening to promote breast cancer aggression","volume":"20","author":"Maller","year":"2021","journal-title":"Nat Mater"},{"key":"B66","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41420-024-01807-9","article-title":"Fatty acid metabolism of immune cells: a new target of tumour immunotherapy","volume":"10","author":"Zhang","year":"2024","journal-title":"Cell Death Discovery"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.5.1928.1928","article-title":"Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells","volume":"87","author":"Urashima","year":"1996","journal-title":"Blood"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3671","article-title":"In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma","volume":"107","author":"Beyer","year":"2006","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.113","article-title":"Multiple myeloma induces the immunosuppressive capacity of distinct myeloid-derived suppressor cell subpopulations in the bone marrow","volume":"26","author":"Van Valckenborgh","year":"2012","journal-title":"Leukemia"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.182.1.240","article-title":"Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1","volume":"182","author":"Li","year":"","journal-title":"J\u00a0Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.113","article-title":"Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells","volume":"100","author":"Castriconi","year":"2003","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3109\/10428191003699563","article-title":"Dysregulation in T helper 1\/T helper 2 cytokine ratios in patients with multiple myeloma","volume":"51","author":"Sharma","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1172\/JCI114392","article-title":"Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias","volume":"84","author":"Bataille","year":"1989","journal-title":"J\u00a0Clin Invest"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1006\/cimm.1999.1586","article-title":"Interleukin-10 reduces natural killer (NK) sensitivity of tumor cells by downregulating NK target structure expression","volume":"198","author":"Tsuruma","year":"1999","journal-title":"Cell Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1002\/art.v67.11","article-title":"Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome","volume":"67","author":"Cifaldi","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.cell.2019.05.054","article-title":"Lipid-associated macrophages control metabolic homeostasis in a trem2-dependent manner","volume":"178","author":"Jaitin","year":"2019","journal-title":"Cell"},{"key":"B77","doi-asserted-by":"publisher","first-page":"157496","DOI":"10.1155\/2012\/157496","article-title":"Bone marrow microenvironment in multiple myeloma progression","volume":"2012","author":"Manier","year":"2012","journal-title":"J BioMed Biotechnol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.05.054","article-title":"Dose-finding study of high-dose simvastatin combined with standard chemotherapy in patients with relapsed or refractory myeloma or lymphoma","volume":"91","author":"Van Der Spek","year":"2006","journal-title":"Haematologica"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.3482","article-title":"Statins are associated with reduced mortality in multiple myeloma","volume":"34","author":"Sanfilippo","year":"2016","journal-title":"J Clin Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-011-1276-2","article-title":"Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma","volume":"90","author":"Hus","year":"2011","journal-title":"Ann Hematol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402501","article-title":"The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells","volume":"16","author":"Van De Donk","year":"2002","journal-title":"Leukemia"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1177\/108155890405200534","article-title":"Simvastatin induces death of multiple myeloma cell lines","volume":"52","author":"Gronich","year":"2004","journal-title":"J Investig Med"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-06-0745","article-title":"Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma","volume":"6","author":"Wong","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1136\/jim-52-05-34","article-title":"Influence of lovastatin on BCL-2 and BAX expression by plasma cells and T lymphocytes in short-term cultures of multiple myeloma bone marrow mononuclear cells","volume":"56","author":"Dmoszynska","year":"2004","journal-title":"Pol J Pharmacol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.01.022","article-title":"Induction of apoptosis in multiple myeloma cells by a statin-thalidomide combination can be enhanced by p38 MAPK inhibition","volume":"37","author":"Slawinska-Brych","year":"2013","journal-title":"Leuk Res"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2013.169","article-title":"Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates","volume":"10","author":"Gronich","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4181","article-title":"Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small-cell lung cancer in preclinical models","volume":"22","author":"Svensson","year":"2016","journal-title":"Nat Med"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2016.4887","article-title":"Silybin suppresses cell proliferation and induces apoptosis of multiple myeloma cells via the PI3K\/Akt\/mTOR signaling pathway","volume":"13","author":"Feng","year":"2016","journal-title":"Mol Med Rep"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S270090","article-title":"Novel small molecular compound AE-848 potently induces human multiple myeloma cell apoptosis by modulating the NF-kappaB and PI3K\/akt\/mTOR signaling pathways","volume":"13","author":"Xu","year":"2020","journal-title":"Onco Targets Ther"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.102","article-title":"Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism","volume":"30","author":"Soriano","year":"2016","journal-title":"Leukemia"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2008.07.012","article-title":"HMG-CoA reductase inhibitor simvastatin overcomes bortezomib-induced apoptosis resistance by disrupting a geranylgeranyl pyrophosphate-dependent survival pathway","volume":"374","author":"Fuchs","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1111\/bph.v178.23","article-title":"Targeting lipid metabolism in multiple myeloma cells: Rational development of a synergistic strategy with proteasome inhibitors","volume":"178","author":"Xu","year":"2021","journal-title":"Br J Pharmacol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"426","DOI":"10.3390\/ph13120426","article-title":"Monoclonal antibodies: leading actors in the relapsed\/refractory multiple myeloma treatment","volume":"13","author":"Mor\u00e9","year":"2020","journal-title":"Pharm (Basel)"},{"key":"B94","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.3390\/cancers16132337","article-title":"Bispecific antibodies for the management of relapsed\/refractory multiple myeloma","volume":"16","author":"Tacchetti","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B95","doi-asserted-by":"publisher","first-page":"112043","DOI":"10.1016\/j.intimp.2024.112043","article-title":"Current status of bispecific antibodies and CAR-T therapies in multiple myeloma","volume":"134","author":"Szlasa","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-05056-7","article-title":"Phase I study of opaganib, an oral sphingosine kinase 2-specific inhibitor, in relapsed and\/or refractory multiple myeloma","volume":"102","author":"Kang","year":"2023","journal-title":"Ann Hematol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"3288","DOI":"10.1182\/blood-2024-206682","article-title":"Targeting the PI3K\/AKT pathway and fatty acid synthase in AL amyloidosis: mechanistic insights and therapeutic implications","volume":"144","author":"Zvida-Bloch","year":"2024","journal-title":"Blood"},{"key":"B98","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.1182\/blood.V126.23.4198.4198","article-title":"Long term statin use and risk of multiple myeloma among 15.5 million Taiwanese adults: A retrospective cohort study","volume":"126","author":"Chiu","year":"2015","journal-title":"Blood"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-537555","article-title":"A phase 1 study of the PI3Kdelta inhibitor idelalisib in patients with relapsed\/refractory mantle cell lymphoma (MCL)","volume":"123","author":"Kahl","year":"2014","journal-title":"Blood"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-019-0291-9","article-title":"Mitochondrial metabolism promotes adaptation to proteotoxic stress","volume":"5","author":"Tsvetkov","year":"2019","journal-title":"Nat Chem Biol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0227455","article-title":"Concurrent lipidomics and proteomics on Malignant plasma cells from multiple myeloma patients: Probing the lipid metabolome","volume":"15","author":"Mohamed","year":"2020","journal-title":"PLoS One"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.7150\/jca.69321","article-title":"A new prediction model integrated serum lipid profile for patients with multiple myeloma","volume":"13","author":"Wang","year":"2022","journal-title":"J Cancer"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1111\/cas.v110.10","article-title":"Serum lipidomics for exploring biomarkers of bortezomib therapy in patients with multiple myeloma","volume":"110","author":"Maekawa","year":"2019","journal-title":"Cancer Sci"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.2174\/092986711798184316","article-title":"Proteasome inhibitors and modulators of angiogenesis in multiple myeloma","volume":"18","author":"Ferrarini","year":"2011","journal-title":"Curr Med Chem"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14178","article-title":"MET\/HGF pathway in multiple myeloma: from diagnosis to targeted therapy","volume":"15","author":"Gambella","year":"2015","journal-title":"Expert Rev Mol Diagn"},{"key":"B106","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3390\/cancers13040625","article-title":"The immune microenvironment in multiple myeloma: friend or foe","volume":"13","author":"Lopes","year":"2021","journal-title":"Cancers (Basel)"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1531928\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T07:10:34Z","timestamp":1741158634000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1531928\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":106,"alternative-id":["10.3389\/fonc.2025.1531928"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1531928","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]},"article-number":"1531928"}}